David Cella

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7124341/publications.pdf

Version: 2024-02-01

531 papers	40,725 citations	3933 88 h-index	3182 186 g-index
547 all docs	547 docs citations	547 times ranked	34958 citing authors

#	Article	IF	Citations
1	Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors. BMJ Supportive and Palliative Care, 2023, 13, e344-e351.	1.6	1
2	Comparison of <scp>Patientâ€Reported</scp> Outcomes Measurement Information System Computerized Adaptive Testing Versus Fixed Short Forms in Juvenile Myositis. Arthritis Care and Research, 2023, 75, 381-390.	3.4	6
3	Association of cognitive impairment and breast cancer survivorship on quality of life in younger breast cancer survivors. Journal of Cancer Survivorship, 2022, 16, 812-822.	2.9	10
4	Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals. Patient, 2022, 15, 131-143.	2.7	2
5	Correlates of financial toxicity in adult cancer patients and their informal caregivers. Supportive Care in Cancer, 2022, 30, 217-225.	2.2	34
6	Cognitive dysfunction prevalence and associated factors in older breast cancer survivors. Journal of Geriatric Oncology, 2022, 13, 33-39.	1.0	4
7	User-centered development of a smartphone application (Fit2Thrive) to promote physical activity in breast cancer survivors. Translational Behavioral Medicine, 2022, 12, 203-213.	2.4	5
8	Patient-reported outcomes predict overall survival in older patients with acute myeloid leukemia. Journal of Geriatric Oncology, 2022, 13, 935-939.	1.0	9
9	Proposed domains for assessing postpartum recovery: a concept elicitation study. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 9-20.	2.3	18
10	Impact of Blinding on Patient-Reported Outcome Differences Between Treatment Arms in Cancer Randomized Controlled Trials. Journal of the National Cancer Institute, 2022, 114, 471-474.	6.3	15
11	Do You Recall?: Results From a Within-Person Recall Study of the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v2.0 â€“ Physical Function 8c. Value in Health, 2022, 25, 161-166.	0.3	5
12	Generation and Validation of the Patient-Reported Outcome Measurement Information System Itch Questionnaireâ€“Child (PIQ-C) to Measure the Impact of Itch on Life Quality. Journal of Investigative Dermatology, 2022, 142, 1309-1317.e1.	0.7	6
13	Symptom experience of limited cutaneous systemic sclerosis from the Patientsâ€™ perspective: A qualitative studyâœ°,âœ°âœ°,â˜…,â˜…â˜…. Seminars in Arthritis and Rheumatism, 2022, 52, 151926.	3.4	12
14	Quality-of-life methodology in hormone receptorâ€“positive advanced breast cancer: Current tools and perspectives for the future. Cancer Treatment Reviews, 2022, 102, 102321.	7.7	4
15	Optimization of a technologyâ€supported physical activity promotion intervention for breast cancer survivors: Results from Fit2Thrive. Cancer, 2022, 128, 1122-1132.	4.1	13
16	Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108). Journal of Clinical Oncology, 2022, 40, 978-987.	1.6	86
17	Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients. Supportive Care in Cancer, 2022, 30, 3613-3623.	2.2	5
18	Effects of patient-reported outcome assessment order. Clinical Trials, 2022, 19, 307-315.	1.6	2

#	Article	IF	Citations
19	Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 292-303.	10.7	42
20	The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: Guidance for Use in Research and Clinical Practice. , 2022, , 79-104.		5
21	Measuring PROMISÂ® Global Health in Early Childhood. Journal of Pediatric Psychology, 2022, 47, 523-533.	2.1	3
22	Measuring PROMISÂ® Emotional Distress in Early Childhood. Journal of Pediatric Psychology, 2022, 47, 547-558.	2.1	14
23	Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptorâ€"Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation. JAMA Oncology, 2022, 8, 579.	7.1	27
24	Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology, 2022, 40, 2138-2147.	1.6	40
25	Youth Well-being During the COVID-19 Pandemic. Pediatrics, 2022, 149, .	2.1	23
26	Measuring PROMISÂ® Social Relationships in Early Childhood. Journal of Pediatric Psychology, 2022, , .	2.1	0
27	Psychometric Considerations in Developing PROMISÂ® Measures for Early Childhood. Journal of Pediatric Psychology, 2022, 47, 510-522.	2.1	4
28	Bringing PROMIS to Early Childhood: Introduction and Qualitative Methods for the Development of Early Childhood Parent Report Instruments. Journal of Pediatric Psychology, 2022, 47, 500-509.	2.1	7
29	The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials. Arthritis Research and Therapy, 2022, 24, 83.	3.5	4
30	Assessing Aspects of Social Relationships in Youth Across Middle Childhood and Adolescence: The NIH Toolbox Pediatric Social Relationship Scales. Journal of Pediatric Psychology, 2022, 47, 991-1002.	2.1	1
31	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncology, The, 2022, 23, 768-780.	10.7	23
32	Patient-reported outcomes: what really matters to patients? â€" Authors' reply. Lancet Oncology, The, 2022, 23, e199.	10.7	0
33	Protocol for a type 2 hybrid effectiveness-implementation study expanding, implementing and evaluating electronic health record-integrated patient-reported symptom monitoring in a multisite cancer centre. BMJ Open, 2022, 12, e059563.	1.9	4
34	Integration of Palliative and Supportive Care Into the Management of Genitourinary Malignancies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 341-350.	3.8	2
35	Age-related health deficits and five-year mortality among older, long-term cancer survivors. Journal of Geriatric Oncology, 2022, 13, 1023-1030.	1.0	1
36	Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. Neuroendocrinology, 2021, 111, 850-862.	2.5	4

#	Article	IF	Citations
37	What Is an Important Difference in Gait Speed in Adults With Knee Osteoarthritis?. Arthritis Care and Research, 2021, 73, 559-565.	3.4	16
38	Conversion of Functional Assessment of Chronic Illness Therapyâ€"Fatigue to Patientâ€Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials. Arthritis Care and Research, 2021, 73, 481-488.	3.4	4
39	The impact of fear of cancer recurrence on healthcare utilization among longâ€term breast cancer survivors recruited through ECOGâ€ACRIN trials. Psycho-Oncology, 2021, 30, 279-286.	2.3	17
40	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. Journal of Scleroderma and Related Disorders, 2021, 6, 66-76.	1.7	12
41	Characteristics and impacts of itch in children with inflammatory skin disorders*. British Journal of Dermatology, 2021, 184, 896-904.	1.5	9
42	Selfâ€reported physical activity, sitting time, and mental and physical health among older cancer survivors compared with adults without a history of cancer. Cancer, 2021, 127, 115-123.	4.1	6
43	Clinically Important Differences for Mobility Measures Derived from the Testosterone Trials. Journal of the American Geriatrics Society, 2021, 69, 517-523.	2.6	2
44	Burden of Recurrent Pericarditis on Health-Related Quality of Life. American Journal of Cardiology, 2021, 141, 113-119.	1.6	8
45	Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review. Advances in Therapy, 2021, 38, 969-993.	2.9	11
46	Anxiety Shapes Expectations of Therapeutic Benefit in Phase I Trials for Patients With Advanced Cancer and Spousal Caregivers. JCO Oncology Practice, 2021, 17, e101-e110.	2.9	3
47	Linking Oswestry Disability Index to the PROMIS pain interference CAT with equipercentile methods. Spine Journal, 2021, 21, 1185-1192.	1.3	14
48	Access to Technology and Preferences for an mHealth Intervention to Promote Medication Adherence in Pediatric Acute Lymphoblastic Leukemia: Approach Leveraging Behavior Change Techniques. Journal of Medical Internet Research, 2021, 23, e24893.	4.3	18
49	Responsiveness and convergent validity of the chronic rhinosinusitis patientâ€reported outcome (CRSâ€PRO) measure in CRS patients undergoing endoscopic sinus surgery. International Forum of Allergy and Rhinology, 2021, 11, 1308-1320.	2.8	10
50	Healthâ€related qualityâ€ofâ€life assessment of patients with solid tumors on immunoâ€oncology therapies. Cancer, 2021, 127, 1360-1368.	4.1	10
51	The mediating role of avoidant coping in the relationships between physical, psychological, and social wellbeing and distress in breast cancer survivors. Psycho-Oncology, 2021, 30, 1129-1136.	2.3	12
52	Computerized Adaptive Testing (CAT) and the Future of Measurement-Based Mental Health Care. Administration and Policy in Mental Health and Mental Health Services Research, 2021, 48, 729-731.	2.1	5
53	Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. Journal of the National Cancer Institute, 2021, 113, 1369-1378.	6.3	8
54	Meaningful Change Thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue and Pain Interference Scores in Patients With Rheumatoid Arthritis. Journal of Rheumatology, 2021, 48, 1239-1242.	2.0	12

#	Article	IF	Citations
55	Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept. BMC Cardiovascular Disorders, 2021, 21, 201.	1.7	8
56	Past and Current Practice of Patient-Reported Outcome Measurement in Randomized Cancer Clinical Trials: A Systematic Review. Value in Health, 2021, 24, 585-591.	0.3	42
57	Symptom and needs assessment screening in oncology patients: Alternate outreach methods during COVID-19. Journal of Psychosocial Oncology, 2021, 39, 452-460.	1.2	4
58	<tt>PROsetta</tt>: An R Package for Linking Patient-Reported Outcome Measures. Applied Psychological Measurement, 2021, 45, 014662162110131.	1.0	12
59	Targeted eHealth Intervention to Reduce Breast Cancer Survivorsâ€™ Fear of Recurrence: Results From the FoRtitude Randomized Trial. Journal of the National Cancer Institute, 2021, 113, 1495-1505.	6.3	32
60	OP0239â€...PSYCHOMETRIC EVALUATION OF FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS. Annals of the Rheumatic Diseases, 2021, 80, 146-147.	0.9	2
61	Reliability and meaningful change of the Patientâ€Reported Outcomes Measurement Information System Â® Itch Questionnaire (PIQ) item banks in adults with atopic dermatitis. British Journal of Dermatology, 2021, 185, 438-439.	1.5	1
62	International application of PROMIS computerized adaptive tests: US versus country-specific item parameters can be consequential for individual patient scores. Journal of Clinical Epidemiology, 2021, 134, 1-13.	5.0	10
63	Can the Knee Outcome and Osteoarthritis Score (KOOS) Function Subscale Be Linked to the PROMIS Physical Function to Crosswalk Equivalent Scores?. Clinical Orthopaedics and Related Research, 2021, 479, 2653-2664.	1.5	6
64	Linking Scores with Patient-Reported Health Outcome Instruments:A VALIDATION STUDY AND COMPARISON OF THREE LINKING METHODS. Psychometrika, 2021, 86, 717-746.	2.1	26
65	The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set. Value in Health, 2021, 24, 862-873.	0.3	14
66	Strategies for Effective Implementation of Patient-Reported Outcome Measures in Arthroplasty Practice. Journal of Bone and Joint Surgery - Series A, 2021, 103, e97.	3.0	6
67	Developing a common metric for depression across adulthood: Linking PROMIS depression with the Edinburgh Postnatal Depression Scale.. Psychological Assessment, 2021, 33, 610-618.	1.5	16
68	Meaning and purpose in Huntingtonâ€™s disease: a longitudinal study of its impact on quality of life. Annals of Clinical and Translational Neurology, 2021, 8, 1668-1679.	3.7	8
69	The PROMISâ“‡-Plus-Osteoarthritis of the Knee (OAK) profile measure integrates generic and condition-specific content to enhance relevance and efficiency. Journal of Clinical Epidemiology, 2021, 135, 158-169.	5.0	1
70	Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures. Quality of Life Research, 2021, 30, 2729-2754.	3.1	153
71	Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy. JAMA Oncology, 2021, 7, 1196.	7.1	13
72	Investigating Trends in the Quality of Reporting of Patient-Reported Outcomes in Oncology Over Time: Analysis of 631 Randomized Controlled Trials Published Between 2004 and 2019. Value in Health, 2021, 24, 1715-1719.	0.3	6

#	Article	IF	Citations
73	Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. Gynecologic Oncology, 2021, 163, 392-397.	1.4	0
74	Turkish validation and reliability of the symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Indexâ€29 (LURN SIâ€29) questionnaire in patients with lower urinary tract symptoms. Neurourology and Urodynamics, 2021, 40, 2034-2040.	1.5	2
75	Common patient-reported outcomes across ICHOM Standard Sets: the potential contribution of PROMISÂ®. BMC Medical Informatics and Decision Making, 2021, 21, 259.	3.0	21
76	Oncologistsâ€™ knowledge and perspectives on the use of biosimilars.. Journal of Clinical Oncology, 2021, 39, 35-35.	1.6	2
77	Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patientâ€reported outcomes substudy. Cancer, 2021, , .	4.1	3
78	Optimizing brief, focused assessment of priority symptoms and concerns in recurrent and/or metastatic squamous cell carcinoma of the head and neck: Content validation of the Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Head and Neck Symptom Indexâ€10 (FHNSIâ€10). Health Science Reports, 2021, 4, e401.	1.5	2
79	Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2â€"negative breast cancer: A trajectory analysis of adverse events. Cancer, 2021, 127, 4546-4556.	4.1	3
80	The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials. Cancers, 2021, 13, 5872.	3.7	3
81	Clinically Important Difference for the FACIT-Fatigue Scale in Paroxysmal Nocturnal Hemoglobinuria: A Derivation from International PNH Registry Patient Data. Blood, 2021, 138, 1952-1952.	1.4	9
82	Symptoms and Impacts Reported By Patients with Acute Myeloid Leukemia (AML) in Remission Post-Stem Cell Transplant. Blood, 2021, 138, 278-278.	1.4	0
83	Evaluation of responsiveness and estimation of smallest detectable change and minimal important change scores for the Childhood Atopic Dermatitis Impact Scale. British Journal of Dermatology, 2020, 182, 348-354.	1.5	7
84	Impact of alemtuzumab on health-related quality of life over 6â€‰years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 955-963.	3.0	9
85	Development, Validation, and Interpretation of the PROMIS Itch Questionnaire: A Patient-Reported Outcome Measure for the Quality of Life Impact of Itch. Journal of Investigative Dermatology, 2020, 140, 986-994.e6.	0.7	22
86	A comparison of computer adaptive tests (CATs) and short forms in terms of accuracy and number of items administrated using PROMIS profile. Quality of Life Research, 2020, 29, 213-221.	3.1	61
87	Does recall period matter? Comparing PROMISÂ® physical function with no recall, 24-hr recall, and 7-day recall. Quality of Life Research, 2020, 29, 745-753.	3.1	25
88	HDQLIFE and Neuroâ€QoL Physical Function Measures: Responsiveness in Persons with Huntington's Disease. Movement Disorders, 2020, 35, 326-336.	3.9	10
89	Development of the Functional Assessment of Cancer Therapyâ€"Immune Checkpoint Modulator (FACTâ€ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. Cancer, 2020, 126, 1550-1558.	4.1	26
90	Psychometric properties and responsiveness of Neuro-QoL Cognitive Function in persons with Huntington disease (HD). Quality of Life Research, 2020, 29, 1393-1403.	3.1	8

#	Article	IF	Citations
91	Responsiveness to Change Over Time: An Examination of the Neuro-QoL Social Function Measures in Persons with Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2020, 9, 83-97.	1.9	1
92	Measurement properties of the Patient-Reported Outcomes Measurement Information System Itch Questionnaire item banks in adults with atopic dermatitis. Journal of the American Academy of Dermatology, 2020, 82, 1174-1180.	1.2	17
93	Development and refinement of FoRtitude: An eHealth intervention to reduce fear of recurrence among breast cancer survivors. Psycho-Oncology, 2020, 29, 227-231.	2.3	9
94	Pragmatic Health Assessment in Early Childhood: The PROMISÂ® of Developmentally Based Measurement for Pediatric Psychology. Journal of Pediatric Psychology, 2020, 45, 311-318.	2.1	34
95	Longitudinal changes in symptomâ€based female and male LUTS clusters. Neurourology and Urodynamics, 2020, 39, 393-402.	1.5	6
96	National Quality Forum Guidelines for Evaluating the Scientific Acceptability of Risk-adjusted Clinical Outcome Measures. Annals of Surgery, 2020, 271, 1048-1055.	4.2	17
97	A Scoring Algorithm for Deriving Utility Values from the Neuro-QoL for Patients with Multiple Sclerosis. Medical Decision Making, 2020, 40, 897-911.	2.4	5
98	Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). Journal of Clinical Oncology, 2020, 38, 3841-3850.	1.6	155
99	Meaning and Dignity Therapies for Psychoneurology in Neuropalliative Care: A Vision for the Future. Journal of Palliative Medicine, 2020, 23, 1155-1156.	1.1	13
100	Measurement Properties of 4 Patient-Reported Outcome Measures to Assess Sleep Disturbance in Adults With Atopic Dermatitis. Dermatitis, 2020, 31, 321-327.	1.6	4
101	PROMISÂ® and Neuro-QoL^{TM} measures are valid measures of health-related quality of life among patients with familial chylomicronemia syndrome. Expert Review of Cardiovascular Therapy, 2020, 18, 231-238.	1.5	10
102	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with longâ€term followâ€up of the randomized, openâ€label, phase 3 CheckMate 025 trial. Cancer, 2020, 126, 4156-4167.	4.1	201
103	Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Medication Adherence Scale (PMAS) . Patient Preference and Adherence, 2020, Volume 14, 971-983.	1.8	13
104	Relationship of symptom severity and bother in individuals seeking care for lower urinary tract symptoms. Neurourology and Urodynamics, 2020, 39, 2161-2170.	1.5	4
105	The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer. Breast Cancer Research and Treatment, 2020, 183, 629-638.	2.5	3
106	Patient demographic and psychosocial characteristics associated with 30â€day recall of selfâ€reported lower urinary tract symptoms. Neurourology and Urodynamics, 2020, 39, 1939-1948.	1.5	5
107	Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS ONE, 2020, 15, e0237497.	2.5	21
108	Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. Journal of Clinical Oncology, 2020, 38, 3494-3505.	1.6	28

#	Article	IF	Citations
109	Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD). Quality of Life Research, 2020, 29, 3419-3439.	3.1	9
110	Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOGâ€ACRIN Cancer Research Group (E1302). Cancer Medicine, 2020, 9, 8884-8894.	2.8	5
111	In our patientâ€centered era, it is time we gave patientâ€reported outcomes their due. Cancer, 2020, 126, 2592-2593.	4.1	5
112	Association of atopic dermatitis severity with cognitive function in adults. Journal of the American Academy of Dermatology, 2020, 83, 1349-1359.	1.2	34
113	Symptom burden trajectories experienced by patients with brain tumors. Cancer, 2020, 126, 3341-3351.	4.1	2
114	Validation of the Functional Assessment of Cancer Therapyâ€"Leukemia instrument in patients with acute myeloid leukemia who are not candidates for intensive therapy. Cancer, 2020, 126, 3542-3551.	4.1	6
115	Evaluation of Domains of Patient-Reported Outcome Measures for Recovery After Childbirth. JAMA Network Open, 2020, 3, e205540.	5.9	35
116	Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I. Gynecologic Oncology, 2020, 158, 194-200.	1.4	9
117	Association of itch triggers with atopic dermatitis severity and course in adults. Annals of Allergy, Asthma and Immunology, 2020, 125, 552-559.e2.	1.0	22
118	Time to health-related quality of life improvement analysis was developed to enhance evaluation of modern anticancer therapies. Journal of Clinical Epidemiology, 2020, 127, 9-18.	5.0	10
119	Development of a validated shortâ€form of the Childhood Atopic Dermatitis Impact Scale, the CADISâ€SF15. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1773-1778.	2.4	11
120	Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO). Advances in Therapy, 2020, 37, 1608-1619.	2.9	13
121	Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part II. Gynecologic Oncology, 2020, 158, 201-207.	1.4	5
122	PROMIS-deaf profile measure: cultural adaptation and psychometric validation in American sign language. Journal of Patient-Reported Outcomes, 2020, 4, 44.	1.9	7
123	Applying the COMâ€B model to patientâ€reported barriers to medication adherence in pediatric acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28216.	1.5	14
124	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. Leukemia, 2020, 34, 2451-2459.	7.2	14
125	Measurement properties of the Patientâ€Reported Outcomes Information System (PROMIS^{Â®}) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis*. British Journal of Dermatology, 2020, 183, 891-898.	1.5	26
126	Patientâ€reported Outcome Measures in Emergency Care Research: A Primer for Researchers, Peer Reviewers, and Readers. Academic Emergency Medicine, 2020, 27, 403-418.	1.8	7

#	Article	IF	Citations
127	The increasing value of eHealth in the delivery of patient-centred cancer care. Lancet Oncology, The, 2020, 21, e240-e251.	10.7	162
128	Psychometric Evaluation of the Patient-Related Nausea and Vomiting Management Barriers Questionnaire. Journal of Pain and Symptom Management, 2020, 60, 439-448.	1.2	2
129	Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQÂ©) . Patient Preference and Adherence, 2020, Volume 14, 705-715.	1.8	5
130	Assessing meaning & purpose in life: development and validation of an item bank and short forms for the NIH PROMISÂ®. Quality of Life Research, 2020, 29, 2299-2310.	3.1	27
131	Trends and predictors of multidimensional health-related quality of life after living donor kidney transplantation. Quality of Life Research, 2020, 29, 2355-2374.	3.1	7
132	Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. Journal of Clinical Oncology, 2020, 38, 1875-1886.	1.6	59
133	A New Brief Clinical Assessment of Lower Urinary Tract Symptoms for Women and Men: LURN SI-10. Journal of Urology, 2020, 203, 164-170.	0.4	21
134	Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Journal of Patient-Reported Outcomes, 2020, 4, 106.	1.9	31
135	A cohort study of quality of life in partners of young breast cancer survivors compared to partners of healthy controls. Journal of Patient-Reported Outcomes, 2020, 4, 19.	1.9	10
136	Optimizing Health Information Technologies for Symptom Management in Cancer Patients and Survivors: Usability Evaluation. JMIR Formative Research, 2020, 4, e18412.	1.4	9
137	Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: A qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale. World Journal of Gastrointestinal Oncology, 2020, 12, 205-218.	2.0	10
138	Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators. Journal of Cancer Metastasis and Treatment, 2020, 2020, .	0.8	3
139	Clinical characteristics and health-related quality of life of patients with recurrent pericarditis in the United States: findings from a patient survey. European Heart Journal, 2020, 41, .	2.2	0
140	Pain and Opioid Use in Patients with FLT3 Mutation-Positive Relapsed/Refractory AML: A Subanalysis of Patient-Reported Outcomes from the Admiral Trial. Blood, 2020, 136, 25-26.	1.4	0
141	Improvements in Fatigue Correlate with Changes in Clinical and Hematological Outcomes: Post Hoc Analyses from the Pegasus Study. Blood, 2020, 136, 4-5.	1.4	0
142	Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study. Blood, 2020, 136, 45-46.	1.4	0
143	Understanding Health-Related Quality of Life in Caregivers of Civilians and Service Members/Veterans With Traumatic Brain Injury: Establishing the Reliability and Validity of PROMIS Fatigue and Sleep Disturbance Item Banks. Archives of Physical Medicine and Rehabilitation, 2019, 100, S102-S109.	0.9	26
144	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. Future Oncology, 2019, 15, 1683-1695.	2.4	35

#	Article	IF	Citations
145	Establishing clinically-relevant terms and severity thresholds for Patient-Reported Outcomes Measurement Information SystemÂ® (PROMISÂ®) measures of physical function, cognitive function, and sleep disturbance in people with cancer using standard setting. Quality of Life Research, 2019, 28, 3355-3362.	3.1	40
146	Implementing electronic health recordâ€"integrated screening of patientâ€reported symptoms and supportive care needs in a comprehensive cancer center. Cancer, 2019, 125, 4059-4068.	4.1	46
147	A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC). Clinical Genitourinary Cancer, 2019, 17, 356-365.e1.	1.9	11
148	Use of PROMIS-29Â® in US Veterans: Diagnostic Concordance and Domain Comparisons with the General Population. Journal of General Internal Medicine, 2019, 34, 1452-1458.	2.6	12
149	U.K. utility weights for the <scp>EORTC QLUâ€C10D</scp>. Health Economics (United Kingdom), 2019, 28, 1385-1401.	1.7	30
150	Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings. Journal of Patient-Reported Outcomes, 2019, 3, 10.	1.9	12
151	Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis. Journal of Patient-Reported Outcomes, 2019, 3, 30.	1.9	24
152	Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease. Journal of Huntington's Disease, 2019, 8, 467-482.	1.9	17
153	Screening Properties of the Diagnostic Criteria for Cancer-Related Fatigue. Oncology Research and Treatment, 2019, 42, 440-447.	1.2	9
154	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine, 2019, 381, 2403-2415.	27.0	627
155	Modeling strategies to improve parameter estimates in prognostic factors analyses with patient-reported outcomes in oncology. Quality of Life Research, 2019, 28, 1315-1325.	3.1	4
156	Meaningful differences and validity for the NCCN/FACTâ€P Symptom Index: An analysis of the ALSYMPCA data. Cancer, 2019, 125, 1877-1885.	4.1	4
157	PROMISÂ® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains. Value in Health, 2019, 22, 537-544.	0.3	335
158	Development and Initial Validation of the PROMISÂ®-Plus-HF Profile Measure. Circulation: Heart Failure, 2019, 12, e005751.	3.9	17
159	A new outcome measure for LUTS: Symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Indexâ€29 (LURN SIâ€29) questionnaire. Neurourology and Urodynamics, 2019, 38, 1751-1759.	1.5	22
160	Calibration and initial validation of a general self-efficacy item bank and short form for the NIH PROMISÂ®. Quality of Life Research, 2019, 28, 2513-2523.	3.1	38
161	End-of-life measures in Huntington disease: HDQLIFE Meaning and Purpose, Concern with Death and Dying, and EndÂofÂLife Planning. Journal of Neurology, 2019, 266, 2406-2422.	3.6	9
162	Positive Affect and Well-Being in Huntingtonâ€™s Disease Moderates the Association Between Functional Impairment and HRQOL Outcomes. Journal of Huntington's Disease, 2019, 8, 221-232.	1.9	2

#	Article	IF	Citations
163	The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study. Gynecologic Oncology, 2019, 154, 13-21.	1.4	8
164	Establishing a common metric for selfâ€reported anxiety in patients with prostate cancer: Linking the Memorial Anxiety Scale for Prostate Cancer with PROMIS Anxiety. Cancer, 2019, 125, 3249-3258.	4.1	13
165	Bifactor analysis confirmation of the factorial structure of the Functional Assessment of Cancer Therapyâ€"General (FACTâ€G). Psycho-Oncology, 2019, 28, 1149-1152.	2.3	4
166	Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States. Journal of the American Academy of Dermatology, 2019, 80, 1650-1657.	1.2	20
167	Patientâ€centered engagement and symptom/toxicity monitoring in the new era of tumor nextâ€generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms. Cancer, 2019, 125, 2338-2344.	4.1	7
168	Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome. BMC Cancer, 2019, 19, 274.	2.6	15
169	Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-Bl) among advanced urothelial cancer patients. Supportive Care in Cancer, 2019, 27, 4189-4198.	2.2	26
170	Development and validation of the caregiver roles and responsibilities scale in cancer caregivers. Quality of Life Research, 2019, 28, 1655-1668.	3.1	9
171	Breast cancer survivorsâ€™ preferences for mHealth physical activity interventions: findings from a mixed methods study. Journal of Cancer Survivorship, 2019, 13, 292-305.	2.9	33
172	Inpatient Rehabilitation Quality of Care From the Patientâ€™s Perspective: Effect of Data Collection Timing and Patient Characteristics. Archives of Physical Medicine and Rehabilitation, 2019, 100, 1032-1041.	0.9	6
173	Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subscale (A/CS) in lung cancer patients with involuntary weight loss. Quality of Life Research, 2019, 28, 1641-1653.	3.1	22
174	Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: an AIDS Malignancy Consortium Study (AMC-A03). Quality of Life Research, 2019, 28, 1265-1269.	3.1	4
175	PRO-Bookmarking to Estimate Clinical Thresholds for Patient-reported Symptoms and Function. Medical Care, 2019, 57, S13-S17.	2.4	26
176	Further content validation of the 18-item NCCN/FACT Ovarian Symptom Index and its Disease Related Symptom-Physical (DRS-P) subscale for use in advanced ovarian cancer clinical trials. Health and Quality of Life Outcomes, 2019, 17, 185.	2.4	5
177	Development of the Initial Surveys for the All of Us Research Program. Epidemiology, 2019, 30, 597-608.	2.7	35
178	Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS)-57 and -29 item short forms among kidney transplant recipients. Quality of Life Research, 2019, 28, 815-827.	3.1	66
179	The TBI-CareQOL Measurement System: Development and Preliminary Validation of Health-Related Quality of Life Measures for Caregivers of Civilians and Service Members/Veterans With Traumatic Brain Injury. Archives of Physical Medicine and Rehabilitation, 2019, 100, S1-S12.	0.9	49
180	Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 297-310.	10.7	207

#	Article	IF	Citations
181	Understanding Health-Related Quality of Life of Caregivers of Civilians and Service Members/Veterans With Traumatic Brain Injury: Establishing the Reliability and Validity of PROMIS Social Health Measures. Archives of Physical Medicine and Rehabilitation, 2019, 100, S110-S118.	0.9	28
182	Interviewer- versus self-administration of PROMISÂ® measures for adults with traumatic injury.. Health Psychology, 2019, 38, 435-444.	1.6	28
183	PROMISÂ®: Standardizing the patient voice in health psychology research and practice.. Health Psychology, 2019, 38, 343-346.	1.6	19
184	The Comprehensive Assessment of Self-Reported Urinary Symptoms: A New Tool for Research on Subtypes of Patients with Lower Urinary Tract Symptoms. Journal of Urology, 2019, 201, 1177-1183.	0.4	15
185	The Relationship between Hospitalization and Patient-Reported Outcomes (PROs) in Patients with FLT3-Mutated (FLT3mut+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study. Blood, 2019, 134, 1332-1332.	1.4	5
186	The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study. Blood, 2019, 134, 3850-3850.	1.4	5
187	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2019, 37, TPS684-TPS684.	1.6	11
188	Measurement framework for the Environmental influences on Child Health Outcomes research program. Current Opinion in Pediatrics, 2018, 30, 276-284.	2.0	28
189	Agreement between clinician-rated versus patient-reported outcomes in Huntington disease. Journal of Neurology, 2018, 265, 1443-1453.	3.6	7
190	Conceptual Underpinnings of the Quality of Life in Neurological Disorders (Neuro-QoL): Comparisons of Core Sets for Stroke, Multiple Sclerosis, Spinal Cord Injury, and Traumatic Brain Injury. Archives of Physical Medicine and Rehabilitation, 2018, 99, 1763-1775.	0.9	5
191	Bowel function, sexual function, and symptoms of pelvic organ prolapse in women with and without urinary incontinence. Neurourology and Urodynamics, 2018, 37, 2586-2596.	1.5	16
192	Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial. Supportive Care in Cancer, 2018, 26, 1889-1895.	2.2	6
193	Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30. Pharmacoeconomics, 2018, 36, 225-238.	3.3	77
194	Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302. Annals of Oncology, 2018, 29, 392-397.	1.2	23
195	Development of National Research and Clinical Agendas for Patient-Reported Outcomes in IR: Proceedings from a Multidisciplinary Consensus Panel. Journal of Vascular and Interventional Radiology, 2018, 29, 1-8.	0.5	16
196	PROMISÂ®-29 v2.0 profile physical and mental health summary scores. Quality of Life Research, 2018, 27, 1885-1891.	3.1	327
197	Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805. Quality of Life Research, 2018, 27, 1589-1597.	3.1	1
198	Feasibility of Collecting Patientâ€Reported Outcomes for Inpatient Rehabilitation Quality Reporting. Health Services Research, 2018, 53, 1834-1850.	2.0	3

#	Article	IF	Citations
199	Physical function metric over measure: An illustration with the Patientâ€Reported Outcomes Measurement Information System (PROMIS) and the Functional Assessment of Cancer Therapy (FACT). Cancer, 2018, 124, 153-160.	4.1	30
200	Evaluating cognition in individuals with Huntington disease: Neuro-QoL cognitive functioning measures. Quality of Life Research, 2018, 27, 811-822.	3.1	12
201	Validity and usefulness of a singleâ€item measure of patientâ€reported bother from side effects of cancer therapy. Cancer, 2018, 124, 991-997.	4.1	51
202	Reasons for Seeking Clinical Care for Lower Urinary Tract Symptoms: A Mixed Methods Study. Journal of Urology, 2018, 199, 528-535.	0.4	17
203	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. Journal of Clinical Oncology, 2018, 36, 757-764.	1.6	43
204	Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 1088-1095.	1.6	72
205	Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?. Journal of Clinical Oncology, 2018, 36, 2483-2491.	1.6	17
206	Questionnaires measuring quality of life and satisfaction of patients and their relatives in a palliative care settingâ€"German translation of FAMCARE-2 and the palliative care subscale of FACIT-Pal. Annals of Palliative Medicine, 2018, 7, 420-426.	1.2	15
207	Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome. Medicine (United States), 2018, 97, e13390.	1.0	8
208	Depressive symptom prevalence after intracerebral hemorrhage: a multi-center study. Journal of Patient-Reported Outcomes, 2018, 2, 55.	1.9	5
209	Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexiaâ€"Review and Expert Opinion. International Journal of Molecular Sciences, 2018, 19, 3471.	4.1	21
210	Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR. Clinical Therapeutics, 2018, 40, 2006-2020.e2.	2.5	25
211	Comparing how anxiety is experienced between White and minority patients after local therapy for prostate cancer: A hypothesisgenerating pilot study. Canadian Urological Association Journal, 2018, 13, .	0.6	0
212	Simplified Chinese translation of 13 adult item banks from the Quality of Life in Neurological Disorders (Neuro-QoL). BMC Health Services Research, 2018, 18, 825.	2.2	2
213	Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials. Lancet Diabetes and Endocrinology,the, 2018, 6, 879-890.	11.4	64
214	Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2018, 19, 1404-1416.	10.7	105
215	Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. Annals of Hematology, 2018, 97, 2455-2463.	1.8	16
216	A Comprehensive Conceptual Model of the Experience of Chronic Itch in Adults. American Journal of Clinical Dermatology, 2018, 19, 759-769.	6.7	40

#	Article	IF	Citations
217	Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2018, 150, 119-126.	1.4	15
218	Using PROMIS Pain Interference Items to Improve Quality Measurement in Inpatient Rehabilitation Facilities. Journal of the American Medical Directors Association, 2018, 19, 846-851.e2.	2.5	6
219	General Population Norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale. Value in Health, 2018, 21, 1313-1321.	0.3	81
220	Estimation of a Preference-Based Summary Score for the Patient-Reported Outcomes Measurement Information System: The PROMIS^{Â®}-Preference (PROPr) Scoring System. Medical Decision Making, 2018, 38, 683-698.	2.4	92
221	Validity and Clinically Meaningful Changes in the Psychosexual Daily Questionnaire and Derogatis Interview for Sexual Function Assessment: Results From the Testosterone Trials. Journal of Sexual Medicine, 2018, 15, 997-1009.	0.6	13
222	Response to â€œShifting the conversation on outcomes reportingâ€• American Journal of Transplantation, 2018, 18, 2368-2369.	4.7	2
223	Development and validation of the patient roles and responsibilities scale in cancer patients. Quality of Life Research, 2018, 27, 2923-2934.	3.1	11
224	Patient-reported outcomes with nivolumab in advanced solid cancers. Cancer Treatment Reviews, 2018, 70, 75-87.	7.7	19
225	Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy - Anemia (FACT-An) in patients with anemia associated with chronic kidney disease. Health and Quality of Life Outcomes, 2018, 16, 111.	2.4	23
226	Cross-sectional validation of the PROMIS-Preference scoring system. PLoS ONE, 2018, 13, e0201093.	2.5	46
227	Mental Health, Sleep and Physical Function in Treatment Seeking Women with Urinary Incontinence. Journal of Urology, 2018, 200, 848-855.	0.4	36
228	Evaluation of options for presenting health-states from PROMISÂ® item banks for valuation exercises. Quality of Life Research, 2018, 27, 1835-1843.	3.1	14
229	Important Group Differences on the Functional Assessment of Cancer Therapyâ€"Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma. Value in Health, 2018, 21, 1413-1418.	0.3	7
230	Initial Development and Content Validation of a Health-Related Symptom Index for Persons either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions. Value in Health, 2018, 21, 984-992.	0.3	8
231	Hippocampal functional connectivity is related to self-reported cognitive concerns in breast cancer patients undergoing adjuvant therapy. NeuroImage: Clinical, 2018, 20, 110-118.	2.7	60
232	Symptom Based Clustering of Women in the LURN Observational Cohort Study. Journal of Urology, 2018, 200, 1323-1331.	0.4	20
233	Lessons From the Testosterone Trials. Endocrine Reviews, 2018, 39, 369-386.	20.1	173
234	Cancer symptom response as an oncology clinical trial end point. Expert Review of Quality of Life in Cancer Care, 2018, 3, 35-46.	0.6	10

#	Article	IF	Citations
235	Patient-reported outcomes and quality of life measures in atopic dermatitis. Clinics in Dermatology, 2018, 36, 616-630.	1.6	28
236	Health utility scores from EQ-5D and health-related quality of life in patients with esophageal cancer: a real-world cross-sectional study. Ecological Management and Restoration, 2018, 31, .	0.4	14
237	Refining and supplementing candidate measures of psychological well-being for the NIH PROMISÂ®: qualitative results from a mixed cancer sample. Quality of Life Research, 2018, 27, 2471-2476.	3.1	8
238	Patient-reported outcome measures in Huntington disease: Quality of life in neurological disorders (Neuro-QoL) social functioning measures.. Psychological Assessment, 2018, 30, 450-458.	1.5	9
239	Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial.. Journal of Clinical Oncology, 2018, 36, 3073-3073.	1.6	3
240	Optimizing brief, focused symptom assessment in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): The FHNSI-10.. Journal of Clinical Oncology, 2018, 36, e18743-e18743.	1.6	1
241	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. Journal of Clinical Oncology, 2018, 36, TPS710-TPS710.	1.6	1
242	Assessing the quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) in immuno-oncology (I/O): An application to nivolumab vs. everolimus in previously treated advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2018, 36, 669-669.	1.6	0
243	Improvement of carcinoid syndrome (CS) symptoms and quality of life (QoL) in CS patients treated with somatostatin analogs (SSAs): Results from longitudinal patient surveys.. Journal of Clinical Oncology, 2018, 36, 400-400.	1.6	0
244	Quality of life (QoL) in a phase III trial of pelvic external beam radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk, early stage endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group study.. Journal of Clinical Oncology, 2018, 36, 5593-5593.	1.6	0
245	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2018, 36, TPS4597-TPS4597.	1.6	0
246	Financial toxicity among patients with lung cancer in a publicly funded health care system.. Journal of Clinical Oncology, 2018, 36, 192-192.	1.6	1
247	Patient-Reported Outcomes Validation of the FACT-Leu in Acute Myeloid Leukemia: A Review of Baseline Characteristics in AML2002. Blood, 2018, 132, 3590-3590.	1.4	1
248	Long-term fear of recurrence in young breast cancer survivors and partners. Psycho-Oncology, 2017, 26, 22-28.	2.3	68
249	Avoidant coping and self-efficacy mediate relationships between perceived social constraints and symptoms among long-term breast cancer survivors. Psycho-Oncology, 2017, 26, 982-990.	2.3	27
250	Coping strategies tailored to the management of fear of recurrence and adaptation for Eâ€health delivery: The FoRtitude intervention. Cancer, 2017, 123, 906-910.	4.1	21
251	Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment. JAMA - Journal of the American Medical Association, 2017, 317, 717.	7.4	179
252	Association of Testosterone Levels With Anemia in Older Men. JAMA Internal Medicine, 2017, 177, 480.	5.1	180

#	Article	IF	Citations
253	The Dutchâ€"Flemish PROMIS Physical Function item bank exhibited strong psychometric properties in patients with chronic pain. Journal of Clinical Epidemiology, 2017, 87, 47-58.	5.0	28
254	Parent-reported cognitive function is associated with leukoencephalopathy in children with brain tumors. Quality of Life Research, 2017, 26, 2541-2550.	3.1	9
255	Montreal Accord on Patient-Reported Outcomes (PROs) use series â€" Paper 6: creating national initiatives to support development and useâ€"the PROMIS example. Journal of Clinical Epidemiology, 2017, 89, 148-153.	5.0	15
256	The Validity and Reliability of the Korean Version of the Stigma Scale for Chronic Illness 8-Items (SSCI-8) in Patients with Neurological Disorders. International Journal of Behavioral Medicine, 2017, 24, 288-293.	1.7	7
257	Scale Linking to Enable Patient-Reported Outcome Performance Measures Assessed with Different Patient-Reported Outcome Measures. Value in Health, 2017, 20, 1143-1149.	0.3	9
258	Patientâ€reported outcomes in Huntington's disease: Quality of life in neurological disorders (Neuroâ€QoL) and Huntington's disease healthâ€related quality of life (HDQLIFE) physical function measures. Movement Disorders, 2017, 32, 1096-1102.	3.9	9
259	Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns. NeuroImage: Clinical, 2017, 14, 685-691.	2.7	36
260	Utility of the Hemangioma Severity Scale as a Triage Tool and Predictor of Need for Treatment. Pediatric Dermatology, 2017, 34, 78-83.	0.9	11
261	The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies. European Journal of Cancer, 2017, 87, 21-29.	2.8	26
262	Computerized Adaptive Testing in Pediatric Brain Tumor Clinics. Journal of Pain and Symptom Management, 2017, 54, 289-297.	1.2	12
263	Selection of key health domains from PROMISÂ® for a generic preference-based scoring system. Quality of Life Research, 2017, 26, 3377-3385.	3.1	39
264	Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1411-1422.	10.7	74
265	Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials. Neurotherapeutics, 2017, 14, 934-944.	4.4	52
266	Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study. Gynecologic Oncology, 2017, 147, 98-103.	1.4	23
267	Linking of the quality of life in neurological disorders (Neuro-QoL) to the international classification of functioning, disability and health. Quality of Life Research, 2017, 26, 2435-2448.	3.1	12
268	Reliability and Validity of the HD-PRO-TriadTM, a Health-Related Quality of Life Measure Designed to Assess the Symptom Triad of Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2017, 6, 201-215.	1.9	1
269	Standardizing and personalizing the treat to target (T2T) approach for rheumatoid arthritis using the Patient-Reported Outcomes Measurement Information System (PROMIS): baseline findings on patient-centered treatment priorities. Clinical Rheumatology, 2017, 36, 1729-1736.	2.2	29
270	Responding to the quality imperative to embed mental health care into ambulatory oncology. Cancer, 2017, 123, 382-386.	4.1	4

#	Article	IF	Citations
271	Responsiveness of 8 Patientâ€Reported Outcomes Measurement Information System (PROMIS) measures in a large, communityâ€based cancer study cohort. Cancer, 2017, 123, 327-335.	4.1	69
272	Measuring financial toxicity as a clinically relevant patientâ€reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer, 2017, 123, 476-484.	4.1	522
273	The challenge of measuring intra-individual change in fatigue during cancer treatment. Quality of Life Research, 2017, 26, 259-271.	3.1	11
274	Agitation, Delirium, and Cognitive Outcomes in Intracerebral Hemorrhage. Psychosomatics, 2017, 58, 19-27.	2.5	27
275	The Comparability of Functional Assessment of Chronic Illness Therapy - Fatigue Scores between Cancer and Systemic Sclerosis. Journal of Scleroderma and Related Disorders, 2017, 2, 57-63.	1.7	2
276	Two-item PROMISÂ® global physical and mental health scales. Journal of Patient-Reported Outcomes, 2017, 1, 2.	1.9	145
277	Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCCâ€"A Possible Path Forward. Kidney Cancer, 2017, 1, 31-40.	0.4	10
278	Association of fatigue and depression with circulating levels of proinflammatory cytokines and epidermal growth factor receptor ligands: a correlative study of a placebo-controlled fatigue trial. Cancer Management and Research, 2017, Volume 9, 1-10.	1.9	15
279	A critical evaluation of quality of life in clinical trials of breast cancer patients treated with radiation therapy. Annals of Palliative Medicine, 2017, 6, S223-S232.	1.2	15
280	The impact of sleep disturbances (SD) on quality of life, psychological morbidity, and survival of advanced cancer patients (ACP) and caregivers (CG).. Journal of Clinical Oncology, 2017, 35, 10115-10115.	1.6	1
281	Assessment of established patient reported outcomes (PROs) instruments measuring toxicities and quality of life (QOL) for patients (pts) with head and neck cancer (HNC) treated on ECOG 1308 and 2399 studies.. Journal of Clinical Oncology, 2017, 35, 6074-6074.	1.6	3
282	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. Journal of Clinical Oncology, 2017, 35, TPS4596-TPS4596.	1.6	7
283	Feasibility and acceptability of implementing an electronic patient reported outcome (e-PRO) dysphagia screening tool for routine multidisciplinary care.. Journal of Clinical Oncology, 2017, 35, 155-155.	1.6	0
284	Association between duration of somatostatin analogs (SSAs) use and quality of life in patients with carcinoid syndrome in the United States based on the FACT-G instrument.. Journal of Clinical Oncology, 2017, 35, e15693-e15693.	1.6	0
285	Multimodal therapy for cancer related fatigue in patients with prostate cancer receiving radiotherapy and androgen deprivation therapy.. Journal of Clinical Oncology, 2017, 35, 10114-10114.	1.6	3
286	Beziehung von Symptomen und den Vorteilen einer gesundheitsbezogenen LebensqualitÃt bei Patienten mit Karzinoid-Syndrom: Eine post-hoc-Analyse der Telotristat Ethyl-Studie TELESTAR. , 2017, 55, .		0
287	SAT0620â€…Validation of The Dutch-Flemish Promis Fatigue Item Bank in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 894.2-894.	0.9	0
288	Quality of life with Brain Symptom and Impact Questionnaire in patients with brain metastases. Annals of Palliative Medicine, 2016, 5, 179-189.	1.2	1

#	Article	IF	Citations
289	Calibration of the Dutchâ€Flemish <scp>PROMIS</scp> Pain Behavior item bank in patients with chronic pain. European Journal of Pain, 2016, 20, 284-296.	2.8	18
290	Neuroâ€<scp>Q</scp>oL healthâ€related quality of life measurement system: <scp>V</scp>alidation in <scp>P</scp>arkinson's disease. Movement Disorders, 2016, 31, 725-733.	3.9	46
291	New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system). Quality of Life Research, 2016, 25, 2403-2415.	3.1	27
292	Qualityâ€adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Cancer, 2016, 122, 1108-1115.	4.1	34
293	Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden. Supportive Care in Cancer, 2016, 24, 3695-3703.	2.2	62
294	A PROMIS Measure of Neuropathic Pain Quality. Value in Health, 2016, 19, 623-630.	0.3	39
295	Validity of PROMIS physical function measured in diverse clinical samples. Journal of Clinical Epidemiology, 2016, 73, 112-118.	5.0	168
296	Patient and health care provider perceptions of cancer-related fatigue and pain. Supportive Care in Cancer, 2016, 24, 4357-4363.	2.2	50
297	The Brain Symptom and Impact Questionnaire in brain metastases patients: a prospective long-term follow-up study. CNS Oncology, 2016, 5, 31-40.	3.0	4
298	Using Patient-reported Outcomes to Compare Relative Burden of Cancer: EQ-5D and Functional Assessment of Cancer Therapy-General in Eleven Types of Cancer. Clinical Therapeutics, 2016, 38, 769-777.	2.5	37
299	Using Linear Equating to Map PROMISÂ® Global Health Items and the PROMIS-29ÂV2.0 Profile Measure to the Health Utilities Index MarkÂ3. Pharmacoeconomics, 2016, 34, 1015-1022.	3.3	45
300	Itch in the General Internal Medicine Setting: A Cross-Sectional Study of Prevalence and Quality-of-Life Effects. American Journal of Clinical Dermatology, 2016, 17, 681-690.	6.7	29
301	Research letter: Impact of pruritus on quality of lifeâ€"A systematic review. Journal of the American Academy of Dermatology, 2016, 75, 885-886.e4.	1.2	23
302	HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Quality of Life Research, 2016, 25, 2441-2455.	3.1	39
303	Validation of a short questionnaire to measure symptoms and functional limitations associated with handâ€foot syndrome and mucositis in patients with metastatic renal cell carcinoma. Cancer, 2016, 122, 287-295.	4.1	15
304	Reduced prefrontal activation during working and longâ€term memory tasks and impaired patientâ€reported cognition among cancer survivors postchemotherapy compared with healthy controls. Cancer, 2016, 122, 258-268.	4.1	28
305	Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review. Supportive Care in Cancer, 2016, 24, 3661-3668.	2.2	45
306	Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2016, 17, 994-1003.	10.7	194

#	Article	IF	Citations
307	Health-related quality of life among women with ductal carcinomain situor early invasive breast cancer: validation of the FACT-B (version 4). Expert Review of Quality of Life in Cancer Care, 2016, 1, 99-109.	0.6	17
308	The PROMIS satisfaction with social participation measures demonstrated responsiveness in diverse clinical populations. Journal of Clinical Epidemiology, 2016, 73, 135-141.	5.0	97
309	Comparison of interactive voice response (IVR) with paper administration of instruments to assess functional status, sexual function, and quality of life in elderly men. Quality of Life Research, 2016, 25, 811-821.	3.1	5
310	Overview of the obesity intervention taxonomy and pooled analysis working group. Translational Behavioral Medicine, 2016, 6, 244-259.	2.4	9
311	Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format. Quality of Life Research, 2016, 25, 637-649.	3.1	58
312	A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer. Breast Cancer Research and Treatment, 2016, 155, 77-84.	2.5	12
313	Pazopanib in the treatment of advanced renal cell carcinoma. Therapeutic Advances in Urology, 2016, 8, 61-69.	2.0	24
314	Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis. Lung, 2016, 194, 227-234.	3.3	82
315	Clinical validity of PROMIS Depression, Anxiety, and Anger across diverse clinical samples. Journal of Clinical Epidemiology, 2016, 73, 119-127.	5.0	323
316	PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditions. Journal of Clinical Epidemiology, 2016, 73, 89-102.	5.0	327
317	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN) Tj ETQq1 1 0.784314 rgBT /Overlock 10	13.7	529
318	PROMIS Fatigue Item Bank had Clinical Validity across Diverse Chronic Conditions. Journal of Clinical Epidemiology, 2016, 73, 128-134.	5.0	173
319	Evidence from diverse clinical populations supported clinical validity of PROMIS pain interference and pain behavior. Journal of Clinical Epidemiology, 2016, 73, 103-111.	5.0	145
320	Evaluating Individual Change With the Quality of Life in Neurological Disorders (Neuro-QoL) Short Forms. Archives of Physical Medicine and Rehabilitation, 2016, 97, 650-654.e8.	0.9	47
321	Dose Escalation in Stage III Nonâ€"Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 368.	7.1	1
322	Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 830-841.	3.0	72
323	Dutchâ€"Flemish translation of nine pediatric item banks from the Patient-Reported Outcomes Measurement Information System (PROMIS)Â®. Quality of Life Research, 2016, 25, 761-765.	3.1	28
324	Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805).. Journal of Clinical Oncology, 2016, 34, 5004-5004.	1.6	5

#	Article	IF	Citations
325	Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate. Journal of Community and Supportive Oncology, 2016, 14, 148-154.	0.1	9
326	Comparison of the EORTC STO-22 and the FACT-Ga quality of life questionnaires for patients with gastric cancer. Annals of Palliative Medicine, 2016, 5, 13-21.	1.2	9
327	Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study.. Journal of Clinical Oncology, 2016, 34, 4549-4549.	1.6	3
328	Relationship between quality of life (QoL) and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy: Results from the AFFIRM study.. Journal of Clinical Oncology, 2016, 34, 5060-5060.	1.6	0
329	Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer.. Journal of Clinical Oncology, 2016, 34, 593-593.	1.6	0
330	Death anxiety, psychological distress, and quality of life (QOL) in adolescent and young adult (AYA) cancer patients with hematologic malignancies in early survivorship.. Journal of Clinical Oncology, 2016, 34, 10073-10073.	1.6	0
331	Measurement Equivalence of the Patient Reported Outcomes Measurement Information System (PROMIS) Applied Cognition - General Concerns, Short Forms in Ethnically Diverse Groups. Psychological Test and Assessment Modeling, 2016, 58, 255-307.	0.6	17
332	Measuring social function in diverse cancer populations: Evaluation of measurement equivalence of the Patient Reported Outcomes Measurement Information System (PROMIS) Ability to Participate in Social Roles and Activities short form. Psychological Test and Assessment Modeling, 2016, 58, 403-421.	0.6	8
333	Do patients with brain metastases selected for whole brain radiotherapy have worse baseline quality of life as compared to those for radiosurgery or neurosurgery (with or without whole brain) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5	2.7	27
334	Recruitment and Screening for the Testosterone Trials. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 1105-1111.	3.6	28
335	The impact of events scale: a comparison of frequency versus severity approaches to measuring cancerâ€specific distress. Psycho-Oncology, 2015, 24, 1738-1745.	2.3	29
336	THU0599â€...Validation of the Dutch-Flemish Promis Pain Behavior and Pain Interference Item Banks in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 418.1-418.	0.9	0
337	Validity and reliability of the Patient-Reported Arthralgia Inventory: validation of a newly-developed survey instrument to measure arthralgia. Patient Related Outcome Measures, 2015, 6, 205.	1.2	5
338	Calibration and Validation of the Dutch-Flemish PROMIS Pain Interference Item Bank in Patients with Chronic Pain. PLoS ONE, 2015, 10, e0134094.	2.5	32
339	Patient-reported outcomes as end points and outcome indicators in solid tumours. Nature Reviews Clinical Oncology, 2015, 12, 358-370.	27.6	55
340	Reference values of the Functional Assessment of Chronic Illness Therapyâ€Spiritual Wellâ€Being: A report from the American Cancer Society's studies of cancer survivors. Cancer, 2015, 121, 1838-1844.	4.1	69
341	Development and validation of the functional assessment of cancer therapyâ€“antiangiogenesis subscale. Cancer Medicine, 2015, 4, 690-698.	2.8	11
342	Quality of life associated factors in head and neck cancer patients in a developing country using the FACT-H&N. Journal of Cranio-Maxillo-Facial Surgery, 2015, 43, 274-280.	1.7	22

#	Article	IF	Citations
343	Content validity of the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18). Gynecologic Oncology, 2015, 136, 317-322.	1.4	12
344	Creating meaningful cut-scores for Neuro-QOL measures of fatigue, physical functioning, and sleep disturbance using standard setting with patients and providers. Quality of Life Research, 2015, 24, 575-589.	3.1	68
345	Development and Validation of a Quality-of-Life Instrument for Infantile Hemangiomas. Journal of Investigative Dermatology, 2015, 135, 1533-1539.	0.7	27
346	Anxiety and Health-Related Quality of Life Among Patients With Lowâ€"Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT). Journal of Clinical Oncology, 2015, 33, 740-748.	1.6	36
347	Health-related quality of life measurement in oncology: Advances and opportunities.. American Psychologist, 2015, 70, 175-185.	4.2	44
348	Validation of the Neuro-QoL measurement system in children with epilepsy. Epilepsy and Behavior, 2015, 46, 209-214.	1.7	21
349	Bringing <scp>PROMIS</scp> to practice: Brief and precise symptom screening in ambulatory cancer care. Cancer, 2015, 121, 927-934.	4.1	179
350	Longitudinal Evaluation of PROMIS-29 and FACIT-Dyspnea Short Forms in Systemic Sclerosis. Journal of Rheumatology, 2015, 42, 64-72.	2.0	44
351	Spanish translation and linguistic validation of the quality of life in neurological disorders (Neuro-QoL) measurement system. Quality of Life Research, 2015, 24, 753-756.	3.1	14
352	Bevacizumab and quality of life in advanced cervical cancer. Lancet Oncology, The, 2015, 16, 241-243.	10.7	6
353	Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. Annals of Oncology, 2015, 26, 179-185.	1.2	66
354	U.S. General Population Estimate for â€œExcellentâ€•to â€œPoorâ€•Self-Rated Health Item. Journal of General Internal Medicine, 2015, 30, 1511-1516.	2.6	124
355	Linking Physical and Mental Health Summary Scores from the Veterans RAND 12-Item Health Survey (VR-12) to the PROMISÂ® Global Health Scale. Journal of General Internal Medicine, 2015, 30, 1524-1530.	2.6	91
356	Establishing a common metric for self-reported pain: linking BPI Pain Interference and SF-36 Bodily Pain Subscale scores to the PROMIS Pain Interference metric. Quality of Life Research, 2015, 24, 2305-2318.	3.1	64
357	Validation of the PROMIS physical function measures in a diverse US population-based cohort of cancer patients. Quality of Life Research, 2015, 24, 2333-2344.	3.1	162
358	Establishing a Common Metric for Physical Function: Linking the HAQ-DI and SF-36 PF Subscale to PROMISÂ® Physical Function. Journal of General Internal Medicine, 2015, 30, 1517-1523.	2.6	69
359	Testing the PROMIS Â® Depression measures for monitoring depression in a clinical sample outside the US. Journal of Psychiatric Research, 2015, 68, 140-150.	3.1	33
360	Quality of life in patients with TIA and minor ischemic stroke. Neurology, 2015, 85, 1957-1963.	1.1	55

#	Article	IF	Citations
361	Improvement in patient-reported physical and mental health after parathyroidectomy for primary hyperparathyroidism. Surgery, 2015, 158, 837-845.	1.9	38
362	Agreement Between Responses From Community-Dwelling Persons With Stroke and Their Proxies on the NIH Neurological Quality of Life (Neuro-QoL) Short Forms. Archives of Physical Medicine and Rehabilitation, 2015, 96, 1986-1992.e14.	0.9	33
363	Grading financial toxicity based upon its impact on health-related quality of life (HRQol).. Journal of Clinical Oncology, 2015, 33, 6618-6618.	1.6	6
364	Validation of the Functional Assessment of Cancer Therapy-Breast (FACT-B) quality of life instrument.. Journal of Clinical Oncology, 2015, 33, e17753-e17753.	1.6	10
365	Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial.. Journal of Clinical Oncology, 2015, 33, 403-403.	1.6	24
366	Implementation of distress screening in an oncology setting. Journal of Community and Supportive Oncology, 2015, 13, 423-428.	0.1	18
367	The relationship between health utility, quality of life, and symptom scores in Canadian patients with esophageal cancer.. Journal of Clinical Oncology, 2015, 33, 149-149.	1.6	0
368	Hippocampal memory impairment in breast cancer survivors after chemotherapy measurement using covert testing.. Journal of Clinical Oncology, 2015, 33, 1024-1024.	1.6	2
369	Patient-reported symptoms and Canadian Health Utility scores in esophageal cancer patients.. Journal of Clinical Oncology, 2015, 33, 6607-6607.	1.6	1
370	The Comparability of English, French and Dutch Scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F): An Assessment of Differential Item Functioning in Patients with Systemic Sclerosis. PLoS ONE, 2014, 9, e91979.	2.5	13
371	The Impact of Symptom Burden on Patient Quality of Life in Chronic Myeloid Leukemia. Oncology, 2014, 87, 133-147.	1.9	23
372	Establishing a common metric for depressive symptoms: Linking the BDI-II, CES-D, and PHQ-9 to PROMIS Depression.. Psychological Assessment, 2014, 26, 513-527.	1.5	359
373	Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials. Journal of the National Cancer Institute, 2014, 106, dju129-dju129.	6.3	245
374	Characterizing fatigue associated with sunitinib and its impact on healthâ€related quality of life in patients with metastatic renal cell carcinoma. Cancer, 2014, 120, 1871-1880.	4.1	19
375	Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial. Cancer Medicine, 2014, 3, 1353-1358.	2.8	8
376	The development of a financial toxicity patientâ€reported outcome in cancer: The COST measure. Cancer, 2014, 120, 3245-3253.	4.1	394
377	US Valuation of Health Outcomes Measured Using the PROMIS-29. Value in Health, 2014, 17, 846-853.	0.3	117
378	Self-reported cognitive concerns and abilities: two sides of one coin?. Psycho-Oncology, 2014, 23, 1133-1141.	2.3	123

#	Article	IF	Citations
379	Reply to S. Barni et al and M. Sun et al. Journal of Clinical Oncology, 2014, 32, 3783-3784.	1.6	1
380	Current Challenges in Using Patient-Reported Outcomes for Surgical Care and Performance Measurement. JAMA Surgery, 2014, 149, 505.	4.3	54
381	Linking Fatigue Measures on a Common Reporting Metric. Journal of Pain and Symptom Management, 2014, 48, 639-648.	1.2	37
382	Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 26.e25-26.e31.	1.6	2
383	Content validation of the FACT-Br with patients and health-care professionals to assess quality of life in patients with brain metastases. Journal of Radiation Oncology, 2014, 3, 105-113.	0.7	6
384	Prospective Longitudinal Evaluation of a Symptom Cluster in Breast Cancer. Journal of Pain and Symptom Management, 2014, 47, 721-730.	1.2	66
385	Parent-reported cognition of children with cancer and its potential clinical usefulness. Quality of Life Research, 2014, 23, 1049-1058.	3.1	43
386	Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy. Cancer, 2014, 120, 2902-2909.	4.1	70
387	Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptorâ€"Positive Breast Cancer (E-3193,) Tj ETQq1 1 0.784314 rgBT /Overlo 3948-3958.	1.6	118
388	Patient-Reported Outcomes Measurement Information System (PROMIS): Efficient, standardized tools to measure self-reported health and quality of life. Nursing Outlook, 2014, 62, 339-345.	2.6	147
389	Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncology, The, 2014, 15, 1147-1156.	10.7	181
390	Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment. Quality of Life Research, 2014, 23, 2651-2661.	3.1	141
391	Establishing a common metric for self-reported anxiety: Linking the MASQ, PANAS, and GAD-7 to PROMIS Anxiety. Journal of Anxiety Disorders, 2014, 28, 88-96.	3.2	198
392	Validity of the Neurology Quality-of-Life (Neuro-QoL) measurement system in adult epilepsy. Epilepsy and Behavior, 2014, 31, 77-84.	1.7	47
393	THU0563â€...Validation of the Dutch-Flemish PROMIS Pain Behavior and Pain Interference Item Banks in Patients with Chronic Pain. Annals of the Rheumatic Diseases, 2014, 73, 377.2-377.	0.9	0
394	THU0564â€...Validation of the Dutch-Flemish PROMIS Physical Functioning Item Bank in Patients with Chronic Pain. Annals of the Rheumatic Diseases, 2014, 73, 377.3-378.	0.9	0
395	New English and Spanish social health measures will facilitate evaluating health determinants.. Health Psychology, 2014, 33, 490-499.	1.6	240
396	Q-TWiST analysis of patients with metastatic renal cell carcinoma (mRCC) randomized to pazopanib (PAZ) or sunitinib (SUN).. Journal of Clinical Oncology, 2014, 32, 4581-4581.	1.6	3

#	Article	IF	Citations
397	Relative influence of factors determining a womanâ€™s preference for treatment options in ovarian cancer.. Journal of Clinical Oncology, 2014, 32, 5544-5544.	1.6	2
398	Comparing cancer patient and provider perspectives on fatigue and pain.. Journal of Clinical Oncology, 2014, 32, e17680-e17680.	1.6	1
399	A randomized, double-blind trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronate in patients with high-risk bone metastases from breast cancer (The Odyssey) Tj ETQq1 1 0.784314 rgBT /Over	1.6	1
400	A history of health-related quality of life outcomes in psychiatry. Dialogues in Clinical Neuroscience, 2014, 16, 127-135.	3.7	78
401	Marital distress (MD), quality of life, and psychological morbidity among advanced cancer patients (ACP) in phase I trials and their spousal caregivers (SC).. Journal of Clinical Oncology, 2014, 32, 9578-9578.	1.6	1
402	Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with clear cell renal cell carcinoma (METEOR).. Journal of Clinical Oncology, 2014, 32, TPS4601-TPS4601.	1.6	1
403	Patient-relevant symptoms and impacts of chronic lymphocytic leukemia: Evidence from online social networks-based qualitative research with treated and â€œwatch and waitâ€•patients.. Journal of Clinical Oncology, 2014, 32, e17692-e17692.	1.6	0
404	Assessment of single screening questions for dysphagia for routine clinical use in a tertiary care practice.. Journal of Clinical Oncology, 2014, 32, 102-102.	1.6	0
405	Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia.. Journal of Clinical Oncology, 2014, 32, 259-259.	1.6	0
406	Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer. Quality of Life Research, 2013, 22, 1105-1112.	3.1	52
407	Assessment of self-reported negative affect in the NIH Toolbox. Psychiatry Research, 2013, 206, 88-97.	3.3	52
408	The FACIT-AI, a new tool for assessing symptoms associated with malignant ascites. Gynecologic Oncology, 2013, 128, 187-190.	1.4	18
409	Evaluation of Treatment- and Disease-Related Symptoms in Advanced Head and Neck Cancer: Validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Head and Neck Cancer Symptom Index-22 (NFHNSI-22). Journal of Pain and Symptom Management, 2013, 46, 113-120.	1.2	9
410	Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers. Journal of Bone Oncology, 2013, 2, 154-157.	2.4	15
411	Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. British Journal of Cancer, 2013, 108, 1571-1578.	6.4	56
412	The FACT-G7: a rapid version of the functional assessment of cancer therapy-general (FACT-G) for monitoring symptoms and concerns in oncology practice and research. Annals of Oncology, 2013, 24, 1073-1078.	1.2	109
413	Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: Results from the AFFIRM study.. Journal of Clinical Oncology, 2013, 31, 17-17.	1.6	5
414	Quality of life (QoL) among patients with renal cell carcinoma (RCC) treated with pazopanib versus sunitinib in the COMPARZ study.. Journal of Clinical Oncology, 2013, 31, 346-346.	1.6	5

#	Article	IF	Citations
415	Quality of Life in Patients with Advanced Cancer Using the Functional Assessment of Cancer Therapy-General Assessment Tool: A Literature Review. World Journal of Oncology, 2013, 4, 8-17.	1.5	6
416	Validation of the supplementary quality of life questionnaire for mouth/throat and hand/foot soreness.. Journal of Clinical Oncology, 2013, 31, 9574-9574.	1.6	0
417	Pain and other symptoms in patients with hepatocellular carcinoma (HCC): A qualitative analysis.. Journal of Clinical Oncology, 2013, 31, e15187-e15187.	1.6	2
418	Is there an additional health-related quality of life (HRQL) benefit with abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) beyond that mediated by clinical endpoints?. Journal of Clinical Oncology, 2013, 31, 9617-9617.	1.6	0
419	Development and validation of the functional assessment of cancer therapy: Antiangiogenesis (FACT-AntiA).. Journal of Clinical Oncology, 2013, 31, e20527-e20527.	1.6	0
420	Neuro-QOL. Neurology, 2012, 78, 1860-1867.	1.1	522
421	Quality-of-Life Measures in Children With Neurological Conditions. Neurorehabilitation and Neural Repair, 2012, 26, 36-47.	2.9	72
422	Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma. British Journal of Cancer, 2012, 106, 646-650.	6.4	26
423	Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. European Journal of Cancer, 2012, 48, 311-323.	2.8	43
424	Measuring Health-Related Quality of Life in Leukemia: The Functional Assessment of Cancer Therapy â€“ Leukemia (FACT-Leu) Questionnaire. Value in Health, 2012, 15, 1051-1058.	0.3	103
425	Quality of life in patients with primary and metastatic brain tumors in the literature as assessed by the FACT-Br. World Journal of Oncology, 2012, 3, 280-285.	1.5	6
426	Patientsâ€™ and Health Care Providersâ€™ Evaluation of Quality of Life Issues in Advanced Cancer Using Functional Assessment of Chronic Illness Therapy - Palliative Care Module (FACIT-Pal) Scale. World Journal of Oncology, 2012, 3, 210-216.	1.5	3
427	Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma. Blood, 2012, 120, 235-235.	1.4	0
428	How Item Banks and Their Application Can Influence Measurement Practice in Rehabilitation Medicine: A PROMIS Fatigue Item Bank Example. Archives of Physical Medicine and Rehabilitation, 2011, 92, S20-S27.	0.9	258
429	The Neurology Quality-of-Life Measurement Initiative. Archives of Physical Medicine and Rehabilitation, 2011, 92, S28-S36.	0.9	160
430	Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. Journal of Clinical Epidemiology, 2011, 64, 507-516.	5.0	511
431	Spiritual Well-Being as a Component of Health-Related Quality of Life: The Functional Assessment of Chronic Illness Therapyâ€"Spiritual Well-Being Scale (FACIT-Sp). Religions, 2011, 2, 77-94.	0.6	196
432	Development and Validation of 11 Symptom Indexes to Evaluate Response to Chemotherapy for Advanced Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 268-278.	4.9	40

#	Article	IF	Citations
433	A new index of priority symptoms in advanced ovarian cancer. Gynecologic Oncology, 2011, 120, 214-219.	1.4	41
434	The impact of missing data on estimation of health-related quality of life outcomes: an analysis of a randomized longitudinal clinical trial. Health Services and Outcomes Research Methodology, 2011, 11, 134-144.	1.8	4
435	Self-reported fatigue: one dimension or more? Lessons from the Functional Assessment of Chronic Illness Therapyâ€"Fatigue (FACIT-F) questionnaire. Supportive Care in Cancer, 2011, 19, 1441-1450.	2.2	82
436	Parent-perceived child cognitive function: results from a sample drawn from the US general population. Child's Nervous System, 2011, 27, 285-293.	1.1	31
437	Development of a Parent-Report Cognitive Function Item Bank Using Item Response Theory and Exploration of its Clinical Utility in Computerized Adaptive Testing. Journal of Pediatric Psychology, 2011, 36, 766-779.	2.1	51
438	Beyond Traditional Outcomes: Improving Quality of Life in Patients with Renal Cell Carcinoma. Oncologist, 2011, 16, 23-31.	3.7	39
439	Item Banks for Measuring Emotional Distress From the Patient-Reported Outcomes Measurement Information System (PROMISÂ®): Depression, Anxiety, and Anger. Assessment, 2011, 18, 263-283.	3.1	1,443
440	Does Baseline Health-Related Quality of Life or Symptom Burden Predict Clinical Outcomes in Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib?. Blood, 2011, 118, 1025-1025.	1.4	2
441	Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,. Blood, 2011, 118, 4184-4184.	1.4	5
442	Effects of Etravirine Versus Placebo on Health-Related Quality of Life in Treatment-Experienced HIV Patients as Measured by the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) Questionnaire in the DUET Trials. HIV Clinical Trials, 2010, 11, 18-27.	2.0	13
443	Measuring Social Well-Being in People with Chronic Illness. Social Indicators Research, 2010, 96, 381-401.	2.7	38
444	Efficiency of static and computer adaptive short forms compared to full-length measures of depressive symptoms. Quality of Life Research, 2010, 19, 125-136.	3.1	221
445	Measuring social health in the patient-reported outcomes measurement information system (PROMIS): item bank development and testing. Quality of Life Research, 2010, 19, 1035-1044.	3.1	279
446	Patient-reported outcomes measurement information system (PROMIS) domain names and definitions revisions: further evaluation of content validity in IRT-derived item banks. Quality of Life Research, 2010, 19, 1311-1321.	3.1	165
447	Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: A Gynecologic Oncology Group study. Gynecologic Oncology, 2010, 119, 531-537.	1.4	36
448	Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184. Gynecologic Oncology, 2010, 119, 538-542.	1.4	35
449	Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-Î± in a phase III trial: final results and geographical analysis. British Journal of Cancer, 2010, 102, 658-664.	6.4	51
450	Building a Measure of Fatigue: The Functional Assessment of Chronic Illness Therapy Fatigue Scale. PM and R, 2010, 2, 359-363.	1.6	53

#	Article	IF	Citations
451	Representativeness of the Patient-Reported Outcomes Measurement Information System Internet panel. Journal of Clinical Epidemiology, 2010, 63, 1169-1178.	5.0	383
452	The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005â€"2008. Journal of Clinical Epidemiology, 2010, 63, 1179-1194.	5.0	3,521
453	Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). Journal of Clinical Epidemiology, 2010, 63, 1195-1204.	5.0	299
454	Hospitalizations of Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib: Results From a Randomized Phase III Trial. Blood, 2010, 116, 3826-3826.	1.4	1
455	The use of PROMIS and assessment center to deliver patient-reported outcome measures in clinical research. Journal of Applied Measurement, 2010, 11, 304-14.	0.3	164
456	Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa. Journal of Oncology Practice, 2009, 5, 66-70.	2.5	32
457	Progress in Assessing Physical Function in Arthritis: PROMIS Short Forms and Computerized Adaptive Testing. Journal of Rheumatology, 2009, 36, 2061-2066.	2.0	214
458	A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecologic Oncology, 2009, 112, 543-552.	1.4	208
459	Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Quality of Life Research, 2009, 18, 873-880.	3.1	1,272
460	Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapyâ€"Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer. Value in Health, 2009, 12, 124-129.	0.3	163
461	Quality of life in patients with metastatic renal cell carcinoma: The importance of patient-reported outcomes. Cancer Treatment Reviews, 2009, 35, 733-737.	7.7	34
462	Classical test theory and item response theory/Rasch model to assess differences between patient-reported fatigue using 7-day and 4-week recall periods. Journal of Clinical Epidemiology, 2009, 62, 991-997.	5.0	34
463	Analysis of cytokines in ECOG E4Z02: A phase III randomized study of l-carnitine supplementation for fatigue in patients with cancer. Journal of Clinical Oncology, 2009, 27, 9635-9635.	1.6	0
464	Disease Burden and Treatment Impact Associated with Myelodysplastic Syndromes: Preliminary Findings From a Web-Based Survey.. Blood, 2009, 114, 4522-4522.	1.4	0
465	Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Research and Treatment, 2008, 107, 167-180.	2.5	232
466	Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women. Breast Cancer Research and Treatment, 2008, 109, 515-526.	2.5	64
467	Reliability across studies from the functional assessment of cancer therapy-general (FACT-G) and its subscales: a reliability generalization. Quality of Life Research, 2008, 17, 1137-1146.	3.1	109
468	Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy. Cancer, 2008, 113, 1480-1488.	4.1	16

#	Article	IF	Citations
469	Relationship Between Symptom Change, Objective Tumor Measurements, and Performance Status During Chemotherapy for Advanced Lung Cancer. Clinical Lung Cancer, 2008, 9, 51-58.	2.6	16
470	Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial. Journal of Clinical Oncology, 2008, 26, 3763-3769.	1.6	122
471	The Patient-Reported Outcomes Measurement Information System (PROMIS). Medical Care, 2007, 45, S3-S11.	2.4	2,314
472	Should Health-Related Quality of Life Be Measured in Cancer Symptom Management Clinical Trials? Lessons Learned Using the Functional Assessment of Cancer Therapy. Journal of the National Cancer Institute Monographs, 2007, 2007, 53-60.	2.1	23
473	Psychometric Evaluation and Calibration of Health-Related Quality of Life Item Banks. Medical Care, 2007, 45, S22-S31.	2.4	1,242
474	Standardizing Patient-Reported Outcomes Assessment in Cancer Clinical Trials: A Patient-Reported Outcomes Measurement Information System Initiative. Journal of Clinical Oncology, 2007, 25, 5106-5112.	1.6	363
475	Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health and Quality of Life Outcomes, 2007, 5, 70.	2.4	672
476	A comparison of three sets of criteria for determining the presence of differential item functioning using ordinal logistic regression. Quality of Life Research, 2007, 16, 69-84.	3.1	122
477	The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment. Quality of Life Research, 2007, 16, 133-141.	3.1	514
478	A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. Quality of Life Research, 2007, 16, 1615-1626.	3.1	24
479	Equating EORTC QLQ-C30 and FACT-G scores and its use in oncological research. European Journal of Cancer, 2006, 42, 3169-3177.	2.8	68
480	Factor analysis techniques for assessing sufficient unidimensionality of cancer related fatigue. Quality of Life Research, 2006, 15, 1179-1190.	3.1	106
481	Quality of Life of Postmenopausal Women in the ATAC (â€œArimidexâ€, Tamoxifen, Alone or in) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Cancer Research and Treatment, 2006, 100, 273-284.	2.5	218
482	Measuring the concerns of cancer patients with low platelet counts: the Functional Assessment of Cancer Therapyâ€"Thrombocytopenia (FACT-Th) questionnaire. Supportive Care in Cancer, 2006, 14, 1220-1231.	2.2	19
483	Role of Quality of Life in Men with Metastatic Hormone-Refractory Prostate Cancer: How Does Atrasentan Influence Quality of Life?. European Urology, 2006, 49, 781-789.	1.9	21
484	Baseline quality of life (QOL) as a predictor of tolerance to intraperitoneal (IP) chemotherapy for advanced epithelial ovarian cancer (EOC): A Gynecologic Oncology Group (GOG) study. Journal of Clinical Oncology, 2006, 24, 5007-5007.	1.6	6
485	A randomised crossover comparative study of e-diary (electronic diary) versus paper and pencil collection of quality of life data in patients with locally advanced and metastatic non small cell lung cancer. Journal of Clinical Oncology, 2006, 24, 18536-18536.	1.6	0
486	The Patientâ€™s Experience of Fatigue: A Cross-Sectional Study of Cancer Patients.. Blood, 2006, 108, 3356-3356.	1.4	1

#	Article	IF	Citations
487	Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). The Journal of Supportive Oncology, 2006, 4, 191-9.	2.3	65
488	The FDA and the person with cancer: give PROs a chance. Oncology, 2006, 20, 436.	0.5	2
489	Quality of life and clinical decisions in chemotherapy-induced anemia. Oncology, 2006, 20, 25-8.	0.5	11
490	Defining Higher Order Dimensions of Self-Reported Health. Evaluation and the Health Professions, 2005, 28, 122-141.	1.9	16
491	Clinically Meaningful Improvement in Symptoms and Quality of Life for Patients With Non-Small-Cell Lung Cancer Receiving Gefitinib in a Randomized Controlled Trial. Journal of Clinical Oncology, 2005, 23, 2946-2954.	1.6	107
492	Quality of Life in Lung Cancer: The Validity and Cross-Cultural Applicability of the Functional Assessment of Cancer Therapyâ€"Lung Scale. Hematology/Oncology Clinics of North America, 2005, 19, 389-420.	2.2	40
493	A Comprehensive Method for the Translation and Cross-Cultural Validation of Health Status Questionnaires. Evaluation and the Health Professions, 2005, 28, 212-232.	1.9	490
494	Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 811-9.	2.0	313
495	The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes. Clinical and Experimental Rheumatology, 2005, 23, S53-7.	0.8	251
496	The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Annals of Oncology, 2004, 15, 979-986.	1.2	201
497	The Functional Assessment of Cancer Therapyâ€"Lung and Lung Cancer Subscale assess quality of life and meaningful symptom improvement in lung cancer. Seminars in Oncology, 2004, 31, 11-15.	2.2	71
498	Quality of life considerations in patients with advanced lung cancer. Seminars in Oncology, 2004, 31, 16-20.	2.2	102
499	The functional assessment of cancer therapyâ€"BRM (FACTâ€"BRM): A new tool for the assessment of quality of life in patients treated with biologic response modifiers. Quality of Life Research, 2004, 13, 137-154.	3.1	45
500	Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2004, 22, 2159-2166.	1.6	531
501	A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. Journal of Clinical Epidemiology, 2004, 57, 898-910.	5.0	321
502	Performance of cognitively impaired oncology patients and normal controls on functional MRI tasks. Journal of Clinical Oncology, 2004, 22, 8023-8023.	1.6	1
503	Performance of cognitively impaired oncology patients and normal controls on functional MRI tasks. Journal of Clinical Oncology, 2004, 22, 8023-8023.	1.6	1
504	Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer, 2003, 98, 406-412.	4.1	51

#	Article	IF	Citations
505	Measuring the side effects of taxane therapy in oncology. Cancer, 2003, 98, 822-831.	4.1	231
506	What Are the Most Important Symptom Targets When Treating Advanced Cancer? A Survey of Providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation, 2003, 21, 526-535.	1.3	94
507	Epoetin Alfa Treatment Results in Clinically Significant Improvements in Quality of Life in Anemic Cancer Patients When Referenced to the General Population. Journal of Clinical Oncology, 2003, 21, 366-373.	1.6	192
508	Control of cancer-related anemia with erythropoietic agents:a review of evidence for improved quality of life and clinical outcomes. Annals of Oncology, 2003, 14, 511-519.	1.2	104
509	Measuring quality of life in chronic illness: The functional assessment of chronic illness therapy measurement system. Archives of Physical Medicine and Rehabilitation, 2002, 83, S10-S17.	0.9	201
510	What is a clinically meaningful change on the Functional Assessment of Cancer Therapyâ€"Lung (FACT-L) Questionnaire?Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. Journal of Clinical Epidemiology, 2002, 55, 285-295.	5.0	337
511	Fatigue in cancer patients compared with fatigue in the general United States population. Cancer, 2002, 94, 528-538.	4.1	655
512	Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Quality of Life Research, 2002, 11, 207-221.	3.1	438
513	Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapyâ€"spiritual well-being scale (FACIT-Sp). Annals of Behavioral Medicine, 2002, 24, 49-58.	2.9	1,305
514	Advances in quality of life measurements in oncology patients. Seminars in Oncology, 2002, 29, 60-68.	2.2	63
515	The effects of anemia and anemia treatment on the quality of life of people with cancer. Oncology, 2002, 16, 125-32.	0.5	23
516	A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychology, 2002, 21, 564-72.	1.6	136
517	Topotecan Versus Observation After Cisplatin Plus Etoposide in Extensive-Stage Small-Cell Lung Cancer: E7593â€"A Phase III Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2001, 19, 2114-2122.	1.6	273
518	Comparison of Survival and Quality of Life in Advanced Nonâ€"Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology, 2000, 18, 623-623.	1.6	552
519	Assessment methods for quality of life in cancer patients: the FACIT measurement system. Pharmaceutical Medicine, 2000, 14, 78-81.	0.4	18
520	Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACTâ€B. Breast Cancer Research and Treatment, 1999, 55, 187-197.	2.5	285
521	Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). Quality of Life Research, 1999, 8, 723-731.	3.1	48
522	Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Quality of Life Research, 1999, 8, 181-195.	3.1	374

#	Article	IF	Citations
523	The Effect of Epoetin alfa on Quality of Life in Anemic Cancerâ€ƒPatients. Cancer Practice, 1999, 7, 177-182.	0.7	40
524	Age-related differences in the quality of life of breast carcinoma patients after treatment. Cancer, 1999, 86, 1768-1774.	4.1	285
525	Age-related differences in the quality of life of breast carcinoma patients after treatment. , 1999, 86, 1768.		2
526	Ageâ€related differences in the quality of life of breast carcinoma patients after treatment. Cancer, 1999, 86, 1768-1774.	4.1	5
527	A case for including spirituality in quality of life measurement in oncology. Psycho-Oncology, 1999, 8, 417-428.	2.3	13
528	Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions. , 1998, 17, 547-559.		24
529	Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions. Statistics in Medicine, 1998, 17, 547-559.	1.6	2
530	A short form of the Crisis in Family Systems (CRISYS) in a racially diverse sample of pregnant women. Current Psychology, 0, , 1.	2.8	1
531	Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. Journal of Clinical Oncology, 0, , .	1.6	4